Massachusetts Financial Services Co. MA Lowers Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Massachusetts Financial Services Co. MA lessened its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 7.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 459,045 shares of the company's stock after selling 39,176 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.92% of Immunocore worth $13,542,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its stake in Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after purchasing an additional 960 shares in the last quarter. NEOS Investment Management LLC boosted its stake in shares of Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock valued at $330,000 after buying an additional 1,102 shares during the period. XTX Topco Ltd grew its position in shares of Immunocore by 72.9% during the third quarter. XTX Topco Ltd now owns 15,459 shares of the company's stock worth $481,000 after buying an additional 6,516 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Immunocore during the third quarter worth approximately $739,000. Finally, Assetmark Inc. raised its holdings in Immunocore by 5.3% in the fourth quarter. Assetmark Inc. now owns 32,171 shares of the company's stock valued at $949,000 after acquiring an additional 1,616 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Remove Ads

Insider Activity

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at $63,721,463.20. This represents a 60.40 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 9.10% of the company's stock.

Immunocore Stock Performance

NASDAQ:IMCR traded up $0.77 during mid-day trading on Friday, reaching $26.59. 253,093 shares of the stock were exchanged, compared to its average volume of 443,283. The stock has a market capitalization of $1.33 billion, a P/E ratio of -27.99 and a beta of 0.75. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $62.74. The company has a 50 day simple moving average of $28.93 and a 200-day simple moving average of $30.49. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03.

Analyst Ratings Changes

IMCR has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research report on Wednesday, March 12th. Mizuho dropped their target price on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a report on Thursday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat, Immunocore has an average rating of "Moderate Buy" and a consensus price target of $65.18.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.